Close Menu

Carl Icahn is taking another swing at Genzyme; he is going after four seats on Genzyme’s nine-member board — for himself and for three associates, reports the New York Times. Icahn has not said what his plans might be for Genzyme, though the Times notes that when Icahn wins seats on boards, chief executive officers tend to leave and Genzyme’s Henri Termeer isn’t expected to go without a fight. “I’m sure Henri will fight,” says former Genzyme director Constantine Anagnostopoulos.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.